Grace Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GRCE | HRTX | TNXP | PTX.AX | TENX | ATOS | |
|---|---|---|---|---|---|---|
| Market cap | 38.08M | 56.69M | 87.64M | 60.62M | 67.74M | 21.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.0 | -2.7 | -0.7 | 5.3 | -1.2 | -0.6 |
| Price/book | 0.6 | 9.6 | 0.4 | 3.8 | 0.8 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.67% | −74.77% | −71.36% | +10.87% | −74.05% | −81.29% |
| Today | −1.63% | +4.88% | −1.54% | +3.92% | −1.63% | −9.01% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All GRCE news ›Grace Therapeutics (NASDAQ: GRCE) owner buys shares in three-day Form 4
Posted by Defense World Staff on Oct 19th, 2026 Grace Therapeutics, Inc. (NASDAQ: GRCE) filed a Form 4 showing Opaleye Management Inc. bought 71,065 shares from 10/14/2026 to 10/16/2026. The reported weighted average prices were $1.9349 on…
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
Shares of Omeros Corp (OMER) slumped 15% on Friday after a European Medicines Agency committee upheld a negative opinion on its drug for a serious post-transplant condition, though H.C. Wainwright dismissed the selloff as overdone. The…
Opaleye Management Inc. Adds 14,632 Shares of Grace Therapeutics Inc (GRCE) in Latest 13G Filing
GuruFocus Opaleye Management Inc. Adds 14,632 Shares of Grace Therapeutics Inc (GRCE) in Latest 13G Filing Transaction Overview: A Small but Strategic Addition In a recent regulatory filing, Opaleye Ma
Grace Therapeutics (NASDAQ:GRCE) Upgraded at Wall Street Zen
Posted by Tristan Rich on Oct 15th, 2026 Wall Street Zen upgraded shares of Grace Therapeutics (NASDAQ:GRCE – Free Report) from a strong sell rating to a sell rating in a research note released on Monday morning,Wall Street Zen reports.…
Grace Therapeutics: Opaleye buys 60,490 shares
Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage biopharma company developing GTx-104 and other orphan drug candidates for rare and orphan diseases. - [Form 4] Grace Therapeutics, Inc. Insider Trading Activity Grace Therapeutics:…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net2
- defenseworld.net1
- gurufocus.com1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.